Description
Springer Adjuvant Therapy of Primary Breast Cancer VI 1st Editon 2012 Softbound by Hans-Jörg Senn, Richard D. Gelber, Aron Goldhirsch, Beat Thürlimann
This RRCR-conference-volume marks 'number six' in a 20-year evolution of international conferences on the adjuvant therapy of primary breast cancer. Starting in 1978, a handful of some 80 en thusiastic breast cancer surgeons and oncologists, met in a se cluded mountain resort near st. Gallen in Eastern Switzerland, to exchange their early data of some pioneer trials on adjuvant sys temic therapy of early breast cancer, and to correlate their future research efforts to overcome the frustrating prognostic stagna tion of this dominant neoplastic disease in Western females dur ing the past decades. Repeated every 3-4 years, these St. Gallen International Conferences on Adjuvant Therapy of Primary Breast Cancer have continuously grown in numbers of partici pants and in normative, therapeutic influence by being published in major oncology journals [1-3], the last (6th) conference hav ing taken place from February 25-28, 1998 with more than 1800 attendees from over 50 countries worldwide. What is the fascination of adjuvant therapy in primary (early) breast cancer, and what has changed,during the last 3 years since March 1995, to justify another international gathering of this size, and of the world's leading experts in the field? There is no question, that providing even more effective care and designing appropriate recommendations for the multitudes of patients with so-called early breast cancer or at high risk of developing the disease, remain highly important public health goals. I. Epidemiology and Its Lessons.- Diet and Mammary Gland Carcinogenesis.- Prevention of Breast Cancer: Focus on Chemoprevention.- Estrogen/Hormone Replacement Therapy and the Etiology of Breast Cancer.- II. Genetics of Breast Cancer.- Experimental Pathology and Breast Cancer Genetics: New Technologies.- Update on Breast Cancer Susceptibility Genes.- III. Biology of Breast Cancer: Diagnostic and Prognostic Implications.- IGF-I Physiology and Breast Cancer.- Determination of Clinical Utility of Tumor Markers: A Tumor Marker Utility Grading System.- How Can Prognostic and Predictive Factors in Breast Cancer Be Used in a Practical Way Today?.- Strategies for the Development of Vaccines to Treat Breast Cancer.- IV. In Situ Breast Cancer.- Hypothesis and Practice: Are There Several Types of Treatment for Ductal Carcinoma In Situ of the Breast?.- Ductal Carcinoma In Situ of the Breast: Histological Classification and Genetic Alterations.- Trials of Treatment for Non-invasive Breast Cancer.- Summary.- V. Controversies About the Axilla.- The Axilla: To Clear or Not to Clear? That Is the Question!.- Axillary Clearance in Operable Breast Cancer: Still a Necessity?.- Sentinel Lymphadenectomy: A Safe Answer to Less Axillary Surgery?.- Endoscopic Surgery to the Axilla: A Substitute for Conventional Axillary Clearance?.- VI. Integrated Therapy: Changing Surgical Procedures for Breast Cancer.- Surgical Considerations in Preoperative Chemotherapy of Breast Cancer.- Integration of Plastic Surgery in the Course of Breast-Conserving Surgery for Cancer to Improve Cosmetic Result and Radicality of Tumor Excision.- Summary.- VII. Integrated Therapy: Primary Adjuvant Systemic Therapy.- Is Primary Chemotherapy Useful for All Patients with Primary Invasive Breast Cancer?.- The Primary Use of Endocrine Therapies.- VIII. Integrated Therapy: Radiation Therapy/Endocrine Treatment.- Why and How to Combine Chemotherapy and Radiation Therapy in Breast Cancer Patients.- Novel Approaches Using Radiation Therapies.- Molecular Biology of the Estrogen Receptor Aids in the Understanding of Tamoxifen Resistance and Breast Cancer Prevention with Raloxifene.- Aromatase Inhibitors and Their Use in the Adjuvant Setting.- GnRH Analogues and Ovarian Ablation: Their Integration in the Adjuvant Strategy.- Summary.- IX. Adjuvant Systemic Treatments: Cytotoxic Strategies.- Putting the Taxanes to Work: Unanswered Questions.- Putting Taxanes to Work in Operable Breast Cancer: A Search for Selective Indications from Empirical Studies.- Continuous Infusional Chemotherapy for Early Breast Cancer: The Royal Marsden Hospital Experience.- Tailored Chemotherapy to Equal Toxicity: Is It Possible?.- Anti-angiogenesis Therapy and Strategies for Integrating It with Adjuvant Therapy.- X. Adjuvant Systemic Treatments: Cytotoxics and Their Dosage.- New Developments in High-Dose Chemotherapy for Breast Cancer.- Summary.- XI. Integrated Treatments: Quality of Life.- Quality of Life Assessment in the Adjuvant Setting: Is It Relevant?.- Quality of Life Assessment in the International Breast Cancer Study Group: Past, Present, and Future.- Impact of Different Adjuvant Therapy Strategies on Quality of Life in Breast Cancer Survivors.- Summary.- XII. Clinical Research Around the World: Review of Cooperative Group Trials.- North American Adjuvant Breast Cancer Trials.- International Breast Cancer Study Group Trials.- Nordic Trials of Adjuvant Therapy in Primary Breast Cancer.- The EORTC-Breast Cancer Cooperative Group Clinical Research Programme in Early Breast Cancer.- Italian Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group Trials.- Current Trials of the German Adjuvant Breast Cancer Group (GABG).- XIII. International Consensus Conference on Primary Treatment of the Breast: Update 1998.- International Consensus Panel on the Treatment of Primary Breast Cancer V: Update 1998.